TRNS vs. TXG, EYPT, AEHR, ALNT, CTKB, LAB, SENS, FEIM, QSI, and QTRX
Should you be buying Transcat stock or one of its competitors? The main competitors of Transcat include 10x Genomics (TXG), Eyepoint Pharmaceuticals (EYPT), Aehr Test Systems (AEHR), Allient (ALNT), Cytek Biosciences (CTKB), Standard BioTools (LAB), Senseonics (SENS), Frequency Electronics (FEIM), Quantum-Si (QSI), and Quanterix (QTRX). These companies are all part of the "measuring and control equipment" industry.
Transcat vs. Its Competitors
10x Genomics (NASDAQ:TXG) and Transcat (NASDAQ:TRNS) are both small-cap measuring and control equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.
84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 98.3% of Transcat shares are held by institutional investors. 9.4% of 10x Genomics shares are held by company insiders. Comparatively, 2.8% of Transcat shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
10x Genomics currently has a consensus target price of $13.65, suggesting a potential upside of 4.71%. Transcat has a consensus target price of $112.20, suggesting a potential upside of 48.71%. Given Transcat's stronger consensus rating and higher probable upside, analysts plainly believe Transcat is more favorable than 10x Genomics.
Transcat has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.
In the previous week, 10x Genomics had 5 more articles in the media than Transcat. MarketBeat recorded 10 mentions for 10x Genomics and 5 mentions for Transcat. Transcat's average media sentiment score of 1.47 beat 10x Genomics' score of 1.00 indicating that Transcat is being referred to more favorably in the news media.
Transcat has a net margin of 4.64% compared to 10x Genomics' net margin of -13.13%. Transcat's return on equity of 6.66% beat 10x Genomics' return on equity.
10x Genomics has a beta of 2, suggesting that its share price is 100% more volatile than the S&P 500. Comparatively, Transcat has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500.
Summary
Transcat beats 10x Genomics on 10 of the 16 factors compared between the two stocks.
Get Transcat News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRNS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Transcat Competitors List
Related Companies and Tools
This page (NASDAQ:TRNS) was last updated on 9/20/2025 by MarketBeat.com Staff
